Clinical Insights and Patient Considerations for Frontline TKI Therapy in Advanced uHCC
An expert discusses how treatment selection for first-line (1L) tyrosine kinase inhibitor (TKI) therapy in advanced hepatocellular carcinoma (HCC) requires careful evaluation of multiple factors, including liver function (Child-Pugh status), ECOG performance status, tumor burden, and presence of macrovascular invasion or extrahepatic spread. In reviewing individual cases, clinicians assess liver enzyme levels, α-fetoprotein values, radiographic findings, and comorbidities.
Video Player is loading.
Video content above is prompted by the following:
- From your clinical experience, how do you determine which patients are best suited for 1L systemic TKI therapy for advanced unresectable HCC (uHCC)?
- What factors/details from the patient case (history/diagnostics) are notable?
- What factors do you consider most when making treatment decisions, and how do those factors influence your treatment approach?
- How do you determine which patients would benefit from lenvatinib or sorafenib?
Recent Videos
COMFORT Trials: Applying Evidence to Intermediate-Risk Myelofibrosis
Myelofibrosis Management: Clinical Approaches and Treatment Algorithms With Case-Based Application
Clinical Impact of COCOON: Advancing Dermatologic AE Management
Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing
Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy
Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
